slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,117
Current window 31,081-31,110
Pages 1,371
Rows per page 30
Component
31,081-31,110 of 41,117
02
Immix Biopharma | Investor Presentation Deck | 46 slidesImmix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
03
The slide highlights two distinct pipelines: TSTx (Tissue Specific Therapeutics) and NextGen CAR-T.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Problem (Identify pain)1 hit
06
The slide uses a grouped bar chart to compare clinical outcomes across different patient segments (No BCMA, Yes BCMA, Overall).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
16
The slide compares two disease indications side-by-side with clinical metrics and competitive market context.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Quick Win Big Bet1 hit
17
The table uses a red dashed box to highlight the key clinical data rows (ORR, CR, ICANS, CRS).Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
18
The chart demonstrates deepening clinical responses over time, a key indicator of therapeutic efficacy in oncology trials.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
19
The slide uses a red dashed box to highlight the key efficacy metrics for comparison.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
31
The slide uses a bubble chart to map clinical trial outcomes against patient treatment history and a table to detail specific drug performance metrics.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
46
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo, likely to frame the market opportunity for IMX-120.Immix Biopharma | Investor Presentation Deck | 46 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Situation & Context1 hit
09
Includes extensive disclaimer text regarding cross-trial comparison limitations.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
13
Immix Biopharma | Investor Presentation Deck | 49 slidesImmix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Evidence & ProofLoop · Cost Of Inaction1 hit
22
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
31
Includes survival curves (Kaplan-Meier), tumor imaging, and tumor frequency metrics.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Impact & Next StepsLoop · Pareto Focus1 hit
49
The slide compares efficacy of Humira, Stelara, and Entyvio against placebo in clinical trials.Immix Biopharma | Investor Presentation Deck | 49 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution & Approach1 hit
02
Immix Biopharma | Investor Presentation Deck | 52 slidesImmix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
11
Includes a footer citing FDA approval precedents for similar patient population sizes.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
20
The slide explicitly notes that these are cross-trial comparisons, not head-to-head studies.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations Beat · Solution1 hit
24
The chart demonstrates deepening clinical responses over time, with sCR/CR increasing from 50% to 83%.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
33
Includes survival curves (Kaplan-Meier), median survival bar chart, and bioluminescence imaging of tumor regression.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
35
Includes waterfall charts and longitudinal patient response plots; highlights PFS (progression-free survival) and line of therapy.Immix Biopharma | Investor Presentation Deck | 52 slides · Immix Biopharma
Pitch deck Investor relations 1 hit
02
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · Attention1 hit
04
Innoviz | Results Presentation Deck | 18 slidesInnoviz | Results Presentation Deck | 18 slides · Innoviz
Conference presentation Investor relations Beat · NeedLoop · Why Now1 hit
02
Dense legal text page typical of investor presentations; no charts or visuals.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Setup1 hit
13
The slide highlights a conservative strategy with a high concentration in A-rated bonds and a 3.1-year duration.International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations Beat · Financial Performance OverviewLoop · Cost Of Inaction1 hit
19
The slide presents two distinct tables: one for IFRS (2017-2020) and one for U.S. GAAP (2021-2023).International General Insurance | Results Presentation Deck | 20 slides · International General Insurance
Conference presentation Investor relations 1 hit
02
Invitae | Results Presentation Deck | 28 slidesInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Attention1 hit
03
Invitae | Results Presentation Deck | 28 slidesInvitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Attention1 hit
11
The slide uses stacked bar charts to show revenue composition across four segments: Data/Patient Network, Women's health, Rare diseases/Other, and Oncology.Invitae | Results Presentation Deck | 28 slides · Invitae
Conference presentation Investor relations Beat · Key Performance Indicators OverviewLoop · Zoom In1 hit